May 16, 2017

Mitsubishi Tanabe Pharma announces The Lancet Neurology publication ofthe positive clinical results of Edaravone for ALS
Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President &Representative Director: Masayuki Mitsuka) announced today that the positive clinicalresults of RADICAVA™ (generic name: edaravone; Japan names: RADICUT® BAG for
I.V. Infusion. 30mg, US name: RADICAVA) for an amyotrophic Lateral sclerosis (ALS)
was published in The Lancet Neurology on May 15, 2017 (BST).
Title: Safety and efficacy of edaravone in well defined patients with amyotrophic lateralsclerosis: a randomised, double-blind, placebo-controlled trial
DOI: http://dx.doi.org/10.1016/S1474-4422(17)30115-1
After Edaravone has been marketed for a treatment of acute ischemic stroke in Japan
since April 2001, was approved for an additional indication of amyotrophic lateralsclerosis (ALS). As consequence from ALS approval in Japan at June, 2015, eradavone
was approved in U.S. at May, 2017 following approval in Korea at December, 2015
based on our evaluation of the results of clinical trials in Japan.
The positive clinical results of Edaravone published by The Lancet Neurology showed
the data that, in comparison with placebo, the administration of edaravone over six
months for well defined patients with ALS slowed the decline of physical function byapproximately 33% based on the ALS Functional Rating Scale-Revised (ALSFRS-R).
ALS is an idiopathic neurodegenerative disease in which motor neurons selectivelydegenerate and vanish. Muscle strength declines throughout the entire body, including
the extremity, facial, and respiratory muscles, and muscular atrophy progresses. The
number of patients are said to be 10,000 in japan and 20,000 in U.S. approximately.
Mitsubishi Tanabe Pharma will strive to deliver edaravone (RADICUT®, RADICAVA™) toall patients that need it and will also continue working to contribute to patients healthby discovering innovative drugs that address unmet medical needs.

〈〈For Details, Contact the Following Section〉〉
Corporate Communications Department
Tel +81-6-6205-5211

<Reference Materials>■ MTPA press release (English)
https://www.mt-pharma-america.com/wp-content/uploads/2017/05/MTPA-Edaravo
ne-FDA-Decision-Press-Release_50517-FINAL-Updated.pdf■ About RADICAVA™ (edaravone)
Edaravone is a free-radical scavenger that was discovered by Mitsubishi Tanabe
Pharma. Edaravone has the effect of scavenging free radicals that arise accompanying
cerebral ischemia, controlling the lipid peroxidation reaction, and protecting neurons in
the region of the ischemia and the surrounding region. Accordingly, it is thought thatedaravone has the effect of scavenging free radicals, which increase in ALS, protecting
motor neurons from oxidative stress, and delaying the decline in muscle strength andthe progress of muscular atrophy.
One cycle of administration of RADICAVA™ is a total of 28 days, including both thedosing period and the drug-free period, and that cycle is repeated. Adults receive 60
mg of RADICAVA™ intravenously for 60 minutes once per day. The first cycle has adosing period of 14 consecutive days of administration followed by a drug-free periodof 14 days. In subsequent cycles, patients receive daily infusions for 10 days within a14-day dosing period, followed by a 14-day drug-free period.
■ About The Lancet Neurology
The Lancet Neurology was launched in May, 2002, and is lively monthly journal oforiginal research, review, opinion, and news covering international issues relevant toneurologists worldwide.
The Lancet Neurology’s Impact Factor is 23.468 and ranks first among 193 journals in
the clinical neurology category (2013 Journal Citation Reports®, Thomson Reuters2014). The journal provides an authoritative and independent forum for the highest
quality clinical neurology research, reviews, and news in all areas of global clinicalneurology with a particular focus in the research and treatment of stroke, MS,movement disorders, epilepsy, headache, and dementia.
-Quotated from web siteEnd.